6th December 2017

Roche Diagnostics announces ground breaking partnership discussions with Government to transform cancer testing in patients

 

Diagnosing conditions such as cancer could be transformed as a result of innovative partnerships between Roche Diagnostics, the Government, NHS and academia to create the digital tissue laboratory of the future.

The UK Government has announced, as part of its Life Sciences sector deal, that it’s in discussion with  Roche Diagnostics and partners to support the mainstream implementation of Digital Pathology services across the NHS.  This investment could see the trialling of a new, innovative approach to cancer testing that includes whole slide scanners, image management software and image analysis algorithms for use within the NHS.

The current shortage of pathologists and geographic constraints can make it difficult or lengthy for an expert to provide an opinion on a cancer patient case. Once important patient cases are made available digitally, experts from any location can review them without delay. This means more equal access to experts to provide a timely and accurate diagnosis for cancer patients. 

Additionally, making more information available electronically opens possibilities for the discovery of new treatments and the development of Artificial Intelligence algorithms in Pathology diagnosis.  Overall, patient care  could be transformed by this partnership as the greater efficiency in tissue pathology services will help deliver faster and more accurate test results across the NHS.

Commenting on the announcement, Geoff Twist, Managing Director of Roche Diagnostics UK & Ireland, said:

“Roche Diagnostics is proud to be working with the Government at what is an incredibly exciting time for the future of our NHS.

“For a number of years, Roche has led the way in advances in medicines and diagnostics and we take great pride in our collaborative working relationship with the Government and NHS to deliver the best possible solutions in patient care.

“Today’s announcement from the Government  could help transform tissue pathology services and pave the way for the UK to create a new global industry with Artificial Intelligence and Digital Pathology at its forefront. We are committed to helping the Government moving forward.”

For further details please contact the Roche Diagnostics press office at: 020 3761 4419 or by emailing josh.aulak@fourcommunications.com

 

-  Ends  -

 

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.